European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading

MT Newswires Live
10 Mar

European equities traded in the US as American depositary receipts were falling late Monday morning, dropping 2.31% on the S&P Europe Select ADR Index to 1,411.83.

From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which rose 6.4% and 5.1%, respectively. They were followed by medical device maker EDAP TMS (EDAP) and consumer goods giant Unilever (UL), which were up 4.8% and 3.1%, respectively.

The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and financial services company Banco Santander (SAN), which fell 10% and 5.7%, respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and internet browser company Opera (OPRA), which were down 5.3% each.

From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and utilities company National Grid (NGG), which advanced 11% and 2.8%, respectively. They were followed by biopharmaceutical company TC Biopharm (TCBP) and oil and gas company BP (BP), which increased 2.3% and 1.4%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Verona Pharma (VRNA) and Akari Therapeutics (AKTX), which lost 7.5% and 7.3%, respectively. They were followed by cruise line operator Carnival (CUK) and financial services company Barclays (BCS), which shed 7.2% each.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10